Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St

November 01, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Third Quarter 2024 Results

Key Financial Results

Revenue: US$8.96m (up 21% from 3Q 2023).
Net income: US$947.9m (up from US$91.3m loss in 3Q 2023).
EPS: US$16.65 (up from US$1.64 loss in 3Q 2023).

earnings-and-revenue-growth — NasdaqGS:AGIO Earnings and Revenue Growth November 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Agios Pharmaceuticals EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 5.7%. Earnings per share (EPS) exceeded analyst estimates by 87%.

Looking ahead, revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 1.5% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 2 warning signs for Agios Pharmaceuticals (1 is significant!) that you should be aware of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.